Pharmaceutical R&D powered by Global Business Services has been saved
Pharmaceutical R&D powered by Global Business Services
Re-Imagining operational R&D through GBS
With the average cost to develop a new drug rapidly increasing, there is a significant opportunity for pharmaceutical organisations to leverage Global Business Services (GBS) to act as a strategic transformation asset.
This document highlights key areas of opportunity across the R&D organisation that could be delivered from a GBS model. Additionally, the report highlights key considerations for leaders to keep in mind as they embark on this journey -
- Hyper-focus on patient experience
- Drive innovation through focused partnership models
- Leverage the scale of GBS and harness its global talent pool